Home › Kanser sa Prostate › Pennsylvania › Philadelphia
Pag-aaral pangklinika para sa Kanser sa Prostate sa Philadelphia, PA
44 pag-aaral para sa Kanser sa Prostate ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Philadelphia (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Nagre-recruitPhase 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · 13 mi ang layo
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · 22 mi ang layo
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Nagre-recruitPhase 1
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Philadelphia
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Nagre-recruitPhase 3
- Fox Chase Cancer Center ( Site 0076), Philadelphia
- MidLantic urology ( Site 0022), Bala-Cynwyd · 5 mi ang layo
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Nagre-recruitPhase 3
- MidLantic urology, Bala-Cynwyd · 5 mi ang layo
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Nagre-recruitPhase 2/3
- Fox Chase Cancer Center, Philadelphia
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Nagre-recruitPhase 2
- Philadelphia MultiService Center, Philadelphia, PA, Philadelphia
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Nagre-recruitPhase 3
- Perelman Center for Advanced Medicine ( Site 0067), Philadelphia
- Abramson Cancer Center - Penn Medicine ( Site 0079), Philadelphia
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Nagre-recruitPhase 1/2
- GSK Investigational Site, Philadelphia
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Nagre-recruitPhase 1
- Thomas Jefferson University, Philadelphia
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Nagre-recruit
- MidLantic Urology, Bala-Cynwyd · 5 mi ang layo
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Nagre-recruitPhase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi ang layo
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi ang layo
A Study of Tarlatamab for People With Prostate Cancer
Nagre-recruitPhase 2
- Thomas Jefferson University Hospital, Philadelphia
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1
- Thomas Jefferson University, Philadelphia
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Nagre-recruitPhase 2
- Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Nagre-recruitPhase 3
- Penn Presbyterian Medical Center, Philadelphia
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Nagre-recruitPhase 1
- Thomas Jefferson University Honickman Center, Philadelphia
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Nagre-recruitPhase 1
- Thomas Jefferson University, Philadelphia
PSMA PET Combined With MRI for the Detection of PCa
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
- MidLantic Urology, Philadelphia
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Investigative Site #109, Philadelphia
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Nagre-recruitPhase 3
- Philadelphia Veterans Administration Medical Center, Philadelphia
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi ang layo
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi ang layo
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Nagre-recruitPhase 1
- MidLantic Urology, Bala-Cynwyd · 5 mi ang layo
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Nagre-recruitPhase 1
- Thomas Jefferson University, Philadelphia
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Nagre-recruitPhase 1/2
- Thomas Jefferson University Hospital, Philadelphia
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Nagre-recruitPhase 2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia
TERPS Trial for de Novo Oligometastic Prostate Cancer
Nagre-recruitPhase 2
- Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Nagre-recruitObservasyonal na pag-aaral
- Fox Chase Cancer Center - Temple Health, Philadelphia
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Nagre-recruit
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Nagre-recruitPhase 2/3
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Nagre-recruitPhase 1/2
- Research Site, Philadelphia
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Hypofractionated WPPT With HDR Boost
Nagre-recruitPhase 2
- University of Pennsylvania, Philadelphia
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Nagre-recruitPhase 1
- MidLantic Urology, Bala-Cynwyd · 5 mi ang layo
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Nagre-recruitPhase 4
- Albert Einstein Healthcare Network, Philadelphia
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Nagre-recruitPhase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi ang layo
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi ang layo
Prostate Tissue BioBank
Nagre-recruitObservasyonal na pag-aaral
- University of Pennsylvania, Philadelphia
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
Nagre-recruit
- Fox Chase Cancer Center, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Philadelphia
Pag-aaral para sa Kanser sa Prostate sa ibang lungsod
- New York City, NY103 pag-aaral
- Houston, TX76 pag-aaral
- Los Angeles, CA61 pag-aaral
- Boston, MA59 pag-aaral
- St. Louis, MO46 pag-aaral
- Chicago, IL45 pag-aaral
- San Francisco, CA45 pag-aaral
- Baltimore, MD43 pag-aaral
- Nashville, TN43 pag-aaral
- Seattle, WA42 pag-aaral
- Washington, DC38 pag-aaral
- Dallas, TX36 pag-aaral
Iba pang pag-aaral sa Philadelphia
- Kanser (lahat ng uri)59 pag-aaral
- Kanser sa Suso56 pag-aaral
- Non-Small Cell Lung Cancer51 pag-aaral
- Metastatic Cancer46 pag-aaral
- Colorectal Cancer44 pag-aaral
- Kanser sa Ovary44 pag-aaral
- Kanser sa Baga36 pag-aaral
- Acute Myeloid Leukemia34 pag-aaral
- Pagkabigo ng Puso31 pag-aaral
- Kanser ng Endometrium28 pag-aaral
- Depression26 pag-aaral
- Kanser sa Pancreas26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.